How much funding has Edgewise Therapeutics raised?

Edgewise Therapeutics has raised $585.0M in total funding, most recently a Growth Equity round.

Who are Edgewise Therapeutics's investors?

Edgewise Therapeutics's investors include OrbiMed, US Venture Partners, Braidwell LP, Cormorant Asset Management, Driehaus Capital Management, Invus.

When was Edgewise Therapeutics founded?

Edgewise Therapeutics was founded in 2017.

Where is Edgewise Therapeutics headquartered?

Edgewise Therapeutics is headquartered in Boulder, Colorado, United States.

What industry is Edgewise Therapeutics in?

Edgewise Therapeutics operates in Biotech, Healthcare, Therapeutics.

How many employees does Edgewise Therapeutics have?

Edgewise Therapeutics has 51-200 employees.

Edgewise Therapeutics

IPO

A Movement in Muscle

Public · Boulder, United States · Founded 2017 · $585.0M raised

Biotech

Healthcare

Therapeutics

Headquarters: Boulder, Colorado
Employees: 51–200
Founded: 2017
Business Model: B2B
Website: edgewisetx.com

Total Funding: $585.0M
Last Round: $200.0M Growth EquityApr 2025
Rounds: 4
Type: Public

About

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral small-molecule therapies for serious skeletal and cardiac muscle diseases including Duchenne muscular dystrophy, Becker muscular dystrophy, and hypertrophic cardiomyopathy. Founded in 2017 and headquartered in Boulder, Colorado, the company uses its proprietary muscle biology platform to identify and advance muscle-selective drug candidates with the goal of improving function and quality of life for patients with rare muscle disorders.

Summary

Edgewise Therapeutics is a Biotech company based in Boulder, United States, founded in 2017. It has raised $585.0M in total across 4 rounds, most recently a $200.0M Growth Equity round in Apr 2025. Investors include OrbiMed, US Venture Partners and Braidwell LP.

LinkedIn X (Twitter)